Dongliang Li

Title: Dongliang Li: Innovator in Cancer Research

Introduction

Dongliang Li is a prominent inventor based in Nagano, Japan. He has made significant contributions to the field of cancer research, particularly through his innovative work on tumor antigen peptides. His research aims to enhance the prevention and treatment of cancer, showcasing his dedication to advancing medical science.

Latest Patents

Dongliang Li holds a patent for a tumor antigen peptide. The objective of this patent is to provide a peptide that is specifically presented on cancer cells and cancer stem cells. This invention includes a pharmaceutical composition that is useful for the prevention and/or treatment of cancer, containing the peptide as an active ingredient. The patent has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, along with a polynucleotide encoding the peptide. This innovative approach aims to induce cytotoxic T lymphocytes (CTLs) for effective cancer treatment.

Career Highlights

Throughout his career, Dongliang Li has worked with esteemed institutions such as Sapporo Medical University and Medical & Biological Laboratories Co., Ltd. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Dongliang Li has collaborated with notable colleagues, including Toshihiko Torigoe and Eri Atsuyama. These partnerships have further enriched his research and development efforts in cancer treatment.

Conclusion

Dongliang Li's innovative work in cancer research, particularly his patent on tumor antigen peptides, highlights his commitment to improving cancer prevention and treatment. His contributions to the field are invaluable and continue to inspire future advancements in medical science.